82702-31-6

Usage

Chemical Properties

off-white powder

Upstream product

• 1007-16-5 3-bromo-4-fluorobenzoic acid 
• 403-33-8 methyl 4-flurobenzoate 
• 67-56-1 methanol 
• 78239-65-3 3-bromo-4-fluoro-benzoic acid fluoride 

Downstream Products

• 272130-66-2 methyl 3-allyl-4-fluorobenzoate 
• 334792-21-1 methyl 4-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate 
• 757982-31-3 methyl 4-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 288151-61-1 3-bromo-4-methylthiobenzoic acid methyl ester 
• 198477-81-5 methyl 4-fluoro-3-((trimethylsilyl)ethynyl)benzoate 
• 948018-63-1 3-bromo-4-(4-methyl-piperazin-1-yl)-benzoic acid methyl ester 
• 1001922-29-7 1-(3-bromo-4-fluorophenyl)-2-(2-methylsulfanylpyrimidin-4-yl)ethanone 
• 1197357-83-7 methyl 4-fluoro-3-(pyridin-2-ylethynyl)benzoate 
• 1332637-07-6 methyl 3-bromo-4-(2-(methoxycarbonyl)phenoxy)benzoate 
• 1354955-40-0 4-(3,4-Dichlorophenoxy)-3-ethyl-N-(methylsulfonyl)benzamide 
• 1354960-63-6 4-(3,4-Dichlorophenoxy)-3-ethylbenzoic acid 
• 951989-50-7 3-(3-bromo-4-fluorophenyl)-6-(4-methoxyphenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole 
• 1401243-52-4 3-(3-bromo-4-fluorophenyl)-6-(1-naphthylmethyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole 
• 929884-90-2 3-bromo-4-fluorobenzohydrazide 

Relevant academic research and scientific papers

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

Discovery of dabrafenib: A selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors

Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma.

Syntheses and evaluation of anti-inflammatory, analgesic and ulcerogenic activities of 1,3,4-oxadiazole and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole derivatives

Several 2,5-disubstituted-1,3,4-oxadiazoles (4af) and 3,6-disubstituted-1, 2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (7af) were synthesized and characterized by elemental analyses and spectral data. These compounds were screened for their anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities. Compound 7c showed excellent anti-inflammatory and remarkable analgesic activity with reduced ulcerogenic and lipid peroxidation activity when compared with ibuprofen.

2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF

[Object] Provided is a compound which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient for an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease ind

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

Synthesis and biological activity of imidazopyridine anticoccidial agents: Part I

Coccidiosis is the major cause of morbidity and mortality in the poultry industry. Protozoan parasites of the genus Eimeria invade the intestinal lining of the avian host causing tissue pathology, poor weight gain, and in some cases mortality. Resistance

BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS

A compound having formula (I): wherein: R, A, R1 and R2, are as defined in the specification, and pharmaceutical formulas thereof, and methods of use thereof

HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM

The present invention relates to new phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, N-oxides, pharmaceutically acceptable solvates and pharmaceutica

PGD2 receptor antagonists for the treatment of inflammatory diseases

Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simp

QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS

The present invention relates to quinazoline compounds of formula (I) useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. or a pharmaceutically acceptable derivative thereof, wherein R1, X, R3, x, and ring A are as defined in the present application.